Pre Market
|
||||
|
|
|
|
Regular Hours (Closed)
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| Valuation Estimation |
|
EPS (Current/Estimated)
-31.00/-21.39
|
|
Enterprise Value
8.58M
|
| Balance Sheet |
|
Book Value Per Share
-2.18
|
| Cash Flow |
|
Cash Flow Yield
--
|
| Income Statement |
|
Total Revenue
0
|
|
Operating Revenue Per Share
8.20
|
|
Industry Comparison
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
|
Business Description
|
|||
| InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment ofAlzheimer's, ocular and dermatological indications. |

18.01 

18.35